{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5HT3+receptor+antagonist&page=2",
    "query": {
      "intervention": "5HT3 receptor antagonist",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5HT3+receptor+antagonist&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5HT3+receptor+antagonist&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T11:30:00.400Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01031953",
      "title": "Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breakthrough Nausea and Vomiting",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fosaprepitant dimeglumine",
          "type": "DRUG"
        },
        {
          "name": "systemic chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "survey administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 34,
      "start_date": "2008-08",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031953"
    },
    {
      "nct_id": "NCT05317000",
      "title": "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Combination 5-azacytidine and nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Burtness",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-03-23",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317000"
    },
    {
      "nct_id": "NCT01736917",
      "title": "Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapy-Induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Fosaprepitant",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "5HT3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lawrence Einhorn",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "15 Years and older · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2013-01",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-25",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • St Louis, Missouri • Omaha, Nebraska + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736917"
    },
    {
      "nct_id": "NCT00655850",
      "title": "Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2008-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655850"
    },
    {
      "nct_id": "NCT02407600",
      "title": "Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Vomiting",
        "Nausea",
        "Emesis"
      ],
      "interventions": [
        {
          "name": "FOSAPREPITANT (Emend)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ajeet Gajra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2015-04",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02407600"
    },
    {
      "nct_id": "NCT07227597",
      "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer Extensive Stage"
      ],
      "interventions": [
        {
          "name": "Gocatamig",
          "type": "DRUG"
        },
        {
          "name": "I-DXd",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2026-01-29",
      "completion_date": "2030-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 13,
      "location_summary": "Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227597"
    },
    {
      "nct_id": "NCT06863272",
      "title": "A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Ifinatamab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Opevesostat",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2025-07-03",
      "completion_date": "2031-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06863272"
    },
    {
      "nct_id": "NCT07286149",
      "title": "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Neoplasm Malignant"
      ],
      "interventions": [
        {
          "name": "MK-1084",
          "type": "DRUG"
        },
        {
          "name": "Patritumab deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rescue Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2026-04-30",
      "completion_date": "2032-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 4,
      "location_summary": "Clermont, Florida • Chicago, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07286149"
    },
    {
      "nct_id": "NCT07060807",
      "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Patritumab deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2025-07-21",
      "completion_date": "2033-07-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 34,
      "location_summary": "Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Grand Junction",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07060807"
    },
    {
      "nct_id": "NCT07405151",
      "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Oesophageal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "I-DXd",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-27",
      "completion_date": "2028-06-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-30T11:30:00.400Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07405151"
    }
  ]
}